Novo and Orbis sign up to $1.4B deal for oral therapies

Orbis Medicines signed a drug discovery and licensing deal with Novo Nordisk worth up to $1.4 billion to develop oral therapies for cardiometabolic diseases traditionally treated with injectable drugs.